Cancer IVD Market - Global Opportunity Analysis and Industry Forecast, 2018-2025

Diagnostics and Biotech	LI_184838	Pages: NA	Dec 2019 \| 441 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Chapter 1 INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter 2 EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

Chapter 3 MARKET OVERVIEW

3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top Player Positioning/ Market Share Analysis, 2017
3.4. Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities

Chapter 4 CANCER IVD MARKET, BY PRODUCT TYPE

4.1. Overview
4.1.1. Market size and forecast
4.2. Reagents
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Instruments
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Software and Services
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

Chapter 5 CANCER IVD MARKET, BY TECHNIQUE

5.1. Overview
5.1.1. Market size and forecast
5.2. Blood Testing
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Tissue Diagnostics
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

Chapter 6 CANCER IVD MARKET, BY CANCER TYPE

6.1. Overview
6.1.1. Market size and forecast
6.2. Breast Cancer
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Colorectal Cancer
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Lung Cancer
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
6.5. Prostate Cancer
6.5.1. Market size and forecast, by region
6.5.2. Market analysis, by country
6.6. Other Cancer Types
6.6.1. Market size and forecast, by region
6.6.2. Market analysis, by country

Chapter 7 CANCER IVD MARKET, BY END USER

7.1. Overview
7.1.1. Market size and forecast
7.2. Standalone Laboratory
7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country
7.3. Hospitals
7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country
7.4. Academic and Medical Schools
7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country
7.5. Other End User
7.5.1. Market size and forecast, by region
7.5.2. Market analysis, by country

Chapter 8 CANCER IVD MARKET, BY GEOGRAPHY

8.1. Overview
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. North America cancer IVD market, by country
8.2.2.1. U.S. cancer IVD market
8.2.2.1.1. U.S. market, by product type
8.2.2.1.2. U.S. market, by technique
8.2.2.1.3. U.S. market, by cancer type
8.2.2.1.4. U.S. market, by end user
8.2.2.2. Canada cancer IVD market
8.2.2.2.1. Canada market, by product type
8.2.2.2.2. Canada market, by technique
8.2.2.2.3. Canada market, by cancer type
8.2.2.2.4. Canada market, by end user
8.2.2.3. Mexico cancer IVD market
8.2.2.3.1. Mexico market, by product type
8.2.2.3.2. Mexico market, by technique
8.2.2.3.3. Mexico market, by cancer type
8.2.2.3.4. Mexico market, by end user
8.2.3. North America cancer IVD market, by product type
8.2.4. North America cancer IVD market, by technique
8.2.5. North America cancer IVD market, by cancer type
8.2.6. North America cancer IVD market, by end user
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Europe cancer IVD market, by country
8.3.2.1. Germany cancer IVD market
8.3.2.1.1. Germany market, by product type
8.3.2.1.2. Germany market, by technique
8.3.2.1.3. Germany market, by cancer type
8.3.2.1.4. Germany market, by end user
8.3.2.2. France cancer IVD market
8.3.2.2.1. France market, by product type
8.3.2.2.2. France market, by technique
8.3.2.2.3. France market, by cancer type
8.3.2.2.4. France market, by end user
8.3.2.3. UK cancer IVD market
8.3.2.3.1. UK market, by product type
8.3.2.3.2. UK market, by technique
8.3.2.3.3. UK market, by cancer type
8.3.2.3.4. UK market, by end user
8.3.2.4. Italy cancer IVD market
8.3.2.4.1. Italy market, by product type
8.3.2.4.2. Italy market, by technique
8.3.2.4.3. Italy market, by cancer type
8.3.2.4.4. Italy market, by end user
8.3.2.5. Spain cancer IVD market
8.3.2.5.1. Spain market, by product type
8.3.2.5.2. Spain market, by technique
8.3.2.5.3. Spain market, by cancer type
8.3.2.5.4. Spain market, by end user
8.3.2.6. Rest of Europe cancer IVD market
8.3.2.6.1. Rest of Europe market, by product type
8.3.2.6.2. Rest of Europe market, by technique
8.3.2.6.3. Rest of Europe market, by cancer type
8.3.2.6.4. Rest of Europe market, by end user
8.3.3. Europe cancer IVD market, by product type
8.3.4. Europe cancer IVD market, by technique
8.3.5. Europe cancer IVD market, by cancer type
8.3.6. Europe cancer IVD market, by end user
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Asia-Pacific cancer IVD market, by country
8.4.2.1. Japan cancer IVD market
8.4.2.1.1. Japan market, by product type
8.4.2.1.2. Japan market, by technique
8.4.2.1.3. Japan market, by cancer type
8.4.2.1.4. Japan market, by end user
8.4.2.2. China cancer IVD market
8.4.2.2.1. China market, by product type
8.4.2.2.2. China market, by technique
8.4.2.2.3. China market, by cancer type
8.4.2.2.4. China market, by end user
8.4.2.3. India cancer IVD market
8.4.2.3.1. India market, by product type
8.4.2.3.2. India market, by technique
8.4.2.3.3. India market, by cancer type
8.4.2.3.4. India market, by end user
8.4.2.4. Australia cancer IVD market
8.4.2.4.1. Australia market, by product type
8.4.2.4.2. Australia market, by technique
8.4.2.4.3. Australia market, by cancer type
8.4.2.4.4. Australia market, by end user
8.4.2.5. Rest of Asia-Pacific cancer IVD market
8.4.2.5.1. Rest of Asia-Pacific market, by product type
8.4.2.5.2. Rest of Asia-Pacific market, by technique
8.4.2.5.3. Rest of Asia-Pacific market, by cancer type
8.4.2.5.4. Rest of Asia-Pacific market, by end user
8.4.3. Asia-Pacific cancer IVD market, by product type
8.4.4. Asia-Pacific cancer IVD market, by technique
8.4.5. Asia-Pacific cancer IVD market, by cancer type
8.4.6. Asia-Pacific cancer IVD market, by end user
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. LAMEA cancer IVD market, by country
8.5.2.1. Brazil cancer IVD market
8.5.2.1.1. Brazil market, by product type
8.5.2.1.2. Brazil market, by technique
8.5.2.1.3. Brazil market, by cancer type
8.5.2.1.4. Brazil market, by end user
8.5.2.2. Saudi Arabia cancer IVD market
8.5.2.2.1. Saudi Arabia market, by product type
8.5.2.2.2. Saudi Arabia market, by technique
8.5.2.2.3. Saudi Arabia market, by cancer type
8.5.2.2.4. Saudi Arabia market, by end user
8.5.2.3. South Africa cancer IVD market
8.5.2.3.1. South Africa market, by product type
8.5.2.3.2. South Africa market, by technique
8.5.2.3.3. South Africa market, by cancer type
8.5.2.3.4. South Africa market, by end user
8.5.2.4. Rest of LAMEA cancer IVD market
8.5.2.4.1. Rest of LAMEA market, by product type
8.5.2.4.2. Rest of LAMEA market, by technique
8.5.2.4.3. Rest of LAMEA market, by cancer type
8.5.2.4.4. Rest of LAMEA market, by end user
8.5.3. LAMEA cancer IVD market, by product type
8.5.4. LAMEA cancer IVD market, by technique
8.5.5. LAMEA cancer IVD market, by cancer type
8.5.6. LAMEA cancer IVD market, by end user

Chapter 9 COMPANY PROFILES

9.1. Alere Inc.
9.1.1. Operating business segments
9.1.2. Business performance
9.1.3. Key strategic moves and developments
9.2. Bayer AG
9.2.1. Operating business segments
9.2.2. Business performance
9.2.3. Key strategic moves and developments
9.3. Becton, Dickinson and Company
9.3.1. Operating business segments
9.3.2. Business performance
9.3.3. Key strategic moves and developments
9.4. bioMérieux
9.4.1. Operating business segments
9.4.2. Business performance
9.4.3. Key strategic moves and developments
9.5. Bio-Rad Laboratories, Inc.
9.5.1. Operating business segments
9.5.2. Business performance
9.5.3. Key strategic moves and developments
9.6. Danaher Corporation
9.6.1. Operating business segments
9.6.2. Business performance
9.6.3. Key strategic moves and developments
9.7. F. Hoffmann-La Roche AG
9.7.1. Operating business segments
9.7.2. Business performance
9.7.3. Key strategic moves and developments
9.8. Johnson & Johnson
9.8.1. Operating business segments
9.8.2. Business performance
9.8.3. Key strategic moves and developments
9.9. Sysmex Corporation
9.9.1. Operating business segments
9.9.2. Business performance
9.9.3. Key strategic moves and developments
9.10. Thermo Fisher Scientific
9.10.1. Operating business segments
9.10.2. Business performance
9.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,110 Data Pack/Excel ~~$3,840~~ $3,456 Single User License ~~$5,370~~ $4,833 Five User License ~~$6,450~~ $5,805 Enterprise User License ~~$8,995~~ $8,096

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285, Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry